# An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

> **NCT07665437** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 710 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Remibrutinib

## Key facts

- **NCT ID:** NCT07665437
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2031-10-24
- **Final completion:** 2031-10-24
- **Target enrollment:** 710 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665437, "An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*